首页> 外文期刊>Endocrine. >Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion
【24h】

Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion

机译:Copeptin作为精氨酸-加压素/抗利尿激素分泌的标志物,在诊断ADH分泌异常的副肿瘤综合征中

获取原文
获取原文并翻译 | 示例
           

摘要

Direct measurement of arginine-vasopressin/ antidiuretic hormone (AVP/ADH) concentrations is not included in the standard diagnostic procedures for paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Here, we evaluate the potential of copeptin measurement as a surrogate marker of AVP/ADH secretion for the direct diagnosis of suspected SIADH in cancer patients. Forty-six unselected cancer patients with serum sodium concentrations permanently below 135 mmol/L were included in this study. We compared standard diagnostic criteria for SIADH to the measurement of plasma copeptin in relation to osmolality. Normative data for comparison were constructed from 24 healthy controls studied under basal conditions, experimental dehydration, and hypotonic hypervolemia as well as from 222 hospital patients with no suspicion of an altered ADH regulation. Log transformation of copeptin revealed a linear relationship to plasma osmolality in the controls (R - 0.495, p < 0.001). Compared to these normative data, copeptin levels in most cancer patients were inappropriately high for plasma osmolality and were not significantly correlated. These results, suggestive for paraneoplastic SIADH, could be confirmed by conventional diagnostic procedures for SIADH. Current strategies to diagnose SIADH are difficult to perform under outpatients conditions. Our approach allows screening from a single plasma sample for true paraneoplastic ADH oversecretion and thus rapid selection for a specific therapy with an AVP receptor antagonist.
机译:对于不适当的ADH分泌的副肿瘤综合症(SIADH),标准诊断程序不包括直接测量精氨酸-加压素/抗利尿激素(AVP / ADH)的浓度。在这里,我们评估了肽素测量作为AVP / ADH分泌替代指标的潜力,可直接诊断癌症患者中疑似SIADH。这项研究包括了46名血清钠浓度永久低于135 mmol / L的未选癌症患者。我们比较了SIADH的标准诊断标准与血浆渗透素相关的肽素的测量。用于比较的标准数据来自在基础条件,实验性脱水和低渗性高血容量下研究的24名健康对照者,以及来自222名没有怀疑ADH调节改变的住院患者。 copeptin的对数转换显示与对照中血浆渗透压的线性关系(R-0.495,p <0.001)。与这些规范数据相比,大多数癌症患者中的肽素水平血浆渗透压过高,且无显着相关性。这些结果提示副肿瘤性SIADH,可通过常规的SIADH诊断程序予以证实。在门诊病人的条件下,目前难以诊断SIADH的策略。我们的方法允许从单个血浆样品中筛选真正的副肿瘤性ADH过度分泌,从而快速选择具有AVP受体拮抗剂的特定疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号